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Bronchiectasis is a heterogeneous disease in terms of its clinical and functional
presentation. Some isolated parameters have been used to assess the severity of
bronchiectasis or its response to treatment. A study was undertaken to evaluate whether
lung function, dyspnea and extension of the disease are separate entities in the impact of
bronchiectasis upon patients using factor analysis.
Patients with bronchiectasis diagnosed by high-resolution computed tomography (HRCT)
and airflow obstruction defined by FEV1/FVCo70% were included. Data were collected
relating to clinical history, three different clinical ratings of dyspnea (Medical Research
Council (MRC), Borg scale and Basal Dyspnea Index), the extent of bronchiectasis and
functional variables.
A total of 81 patients (mean age (SD): 69.5 (8.7)) years were included. The degree of
dyspnea (MRC) was 1.9 (0.8). Mean FEV1 was 1301ml (56.9% pred.). Four factors were
found that accounted for 84.1% of the total data variance. Factor 1 (45.6% of the data
variance) included the three measurements of dyspnea. Factor 2 (16% variance) comprised
airflow obstruction parameters (FEV1, FEV1/FVC and PEF). Factor 3 (13.8% variance)
included RV/TLC and RV (lung hyperinflation). Factor 4 (8.6% variance) included
bronchiectasis extent. Dyspnea was more closely correlated with lung hyperinflation
(r:0.33–0.54) than with airflow obstruction parameters (r:0.17–0.26).
Conclusions: Airflow obstruction, dyspnea, lung hyperinflation and the lung extent of the
bronchiectasis are four independent entities in the impact of bronchiectasis upon patients.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis 2249Introduction out-patient clinic due to symptoms attributable to bronchi-Bronchiectasis is a chronic lung condition characterized by
irreversible bronchial dilatation due to a vicious circle
comprising clearance system damage, inflammation and
infection of the bronchi.1 In evolutive terms, bronchiectasis
behaves as a chronic and progressive disease with multiple
exacerbations and chronic colonization of the bronchial
mucosa by different pathogenic microorganisms. The ulti-
mate result is altered lung function (generally comprising
irreversible airflow obstruction) and progressive dyspnea
that greatly deteriorates patient’s quality of life.2–4
Several isolated parameters such as functional or micro-
biological variables, clinical data or the extent of the
disease have been used to assess the severity of disease or to
evaluate the effect of several treatments in patients with
steady-state bronchiectasis.5–7 However, the impact of
bronchiectasis varies considerably between patients—as
indicated by the great variability in the clinical picture or
quality of life scores in relation to the same lung function or
extent of bronchiectasis.3,8,9 This seems to indicate that a
single clinical or functional parameter does not suffice to
assess the global effects of bronchiectasis upon patients.
Factor analysis has been shown to be a useful statistical
tool as a hypothesis-generating technique for analyzing the
relationship between multiple measures in evaluating out-
come in clinical studies. It has already been successfully
used by some authors for studying other airway disorders
such as chronic obstructive pulmonary disease (COPD) or
asthma. For example, in patients with asthma, factor
analysis has demonstrated that lung function, airway
hyper-responsiveness and eosinophilic inflammation in spu-
tum are non-overlapping dimensions.10 In COPD, factor
analysis has been applied to study the dissociation between
lung function, the clinical rating of dyspnea, exercise
capacity and lung hyperinflation.11–13 There is growing
controversy about the relationships between lung function,
clinical features—especially dyspnea—and the radiological
extension of disease in patients with bronchiectasis. These
intervariable relationships have usually been analyzed using
simple correlations; we have not found any studies using
factor analysis to assess the multivariate relationship among
these baseline conditions in patients with bronchiectasis.
The present study was designed to analyze whether lung
function, the clinical rating of dyspnea and lung extension of
bronchiectasis as assessed by high-resolution computed
tomography (HRCT) are separate entities offering indepen-
dent information for assessment of the impact of bronch-
iectasis upon patients. For this purpose we applied factor
analysis in well-characterized patients with non-cystic
fibrosis (CF) steady-state bronchiectasis and airflow obstruc-
tion exhibiting a broad range of disease severity.
Methods
Study population
One hundred and thirty-one patients diagnosed in our center
with clinically stable bronchiectasis affecting more than one
lung lobe, or with cystic bronchiectasis, were asked to
participate in the study. All patients were sent to ourectasis. Patients with traction bronchiectasis associated to
advanced interstitial processes (n ¼ 15) were excluded, as
were patients with bronchiectasis subjected to surgical
management (n ¼ 2), individuals who because of mental or
physical impairment were presumed to be unable to
complete the study protocol (n ¼ 11) and patients who
refused to participate (n ¼ 2). Finally, patients without
airflow obstruction defined as a FEV1/FVCo70% were also
excluded (n ¼ 21). Exacerbation was defined as persistent
(424 h) deterioration of at least three respiratory symptoms
(including cough, dyspnea, hemoptysis, increased sputum
purulence or volume, and chest pain) with or without fever,
radiographic deterioration, systemic disturbances, or deteri-
oration in chest signs.6 The study protocol was approved by
our Ethics Committee and is consistent with the principles of
the Declaration of Helsinki.
Dyspnea evaluation
All patients finally included in the study were seen in our
center during 2003 for documentation of the complete
clinical history (CH visit), which included general and
anthropometric data (age, sex and body mass index (BMI)
in kg/m2), and personal disease antecedents of interest and
smoking habit (packs/year). Dyspnea was evaluated prior to
functional testing using three validated scales: a modified
Medical Research Council (MRC) scale,14 the Borg scale15 and
the Basal Dyspnea Index (BDI).16 The modified MRC scale
includes five grades of various physical activities that
provoke dyspnea. The BDI consists of 5 grades for the
categories: functional impartment, magnitude of task and
magnitude of effort. The Borg scale is a visual analog scale
(VAS) of dyspnea which was represented as a value ranging
from 0 to 10 (10 ¼ maximum dyspnea).
Diagnosis and extent of bronchiectasis
Bronchiectasis was diagnosed by HRCT of the chest, with
1mm slices at 10mm intervals in deep inspiration, according
to the criteria of Naidich et al.17 The extent of bronchiec-
tasis was established by a modified scale described by Bhalla
et al.18: each lung lobe (considering lingula and middle lobe
as independent) was scored as 0 (no bronchiectasis), 1
(cylindrical bronchiectasis in a single lung segment), 2
(cylindrical bronchiectasis in more than one lung segment)
or 3 (cystic bronchiectasis). The maximum score was taken
to be 18 points. All HRCT scans were independently
evaluated by two radiologists with extensive experience in
the study of HRCT images of bronchiectasic patients. Kappa
value was calculated for assessment of interobserver
agreement for the diagnosis of bronchiectasis.
Lung function measurement
Lung function testing was performed over the 2 days
following the CH visit, and included forced spirometry with
the measurement of forced expiratory volume in one second
(FEV1), forced vital capacity (FVC) and peak expiratory flow
(PEF) according to the Spanish Society of Respiratory Disease
(SEPAR) guidelines.19 Flow obstruction was defined as the
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Table 1 Patient characteristics (n ¼ 81).
Parameter Mean (SD) Range
Age (yr) 69.5 (8.7) 45–84
Gender M/F 42/39 –
BMI (kg/m2) 28.7 (4.6) 19–41
Dyspnea (MRC) 1.91 (0.88) 0–4
Dyspnea (Borg) 3.44 (1.68) 0–9
Dyspnea (BDI) 6.54 (2.75) 0–12
FEV1 (% predicted) 56.9 (19.4) 17–98
FEV1 (ml) 1301.8 (519) 495–2810
FEV1/FVC 55.1 (10.6) 30.8–69.8
RV (% predicted) 111.8 (32.34) 59–276.3
RV/TLC 125.7 (35.1) 80.9–254.1
HRCT score 4.53 (2.3) 2–14
Quantitative variables were tabulated as the mean, standard
deviation (SD) and range, and qualitative variables as the
absolute value and percentage.
HRCT: high-resolution computed tomography of the chest;
MRC: Medical Research Council dyspnea scale; Postbd: post-
bronchodilator values; FEV1: forced expiratory volume in 1 s;
RV/TLC: ratio between residual volume and total lung
capacity.
M.A. Martı´nez-Garcı´a et al.2250presence of FEV1/FVCo70%. Total lung capacity (TLC) and
residual volume (RV) were measured by the helium dilution
technique. The RV/TLC ratio was accepted as a measure of
pulmonary hyperinflation. Reference values for all lung
function measurements were obtained from Roca et al. for a
mediterranean population.20 All tests were performed by
qualified staff and at the same time in the morning. The
patients were required to be in a clinically stable phase (at
least 4 weeks without exacerbation) for conducting any
clinical or functional test.
Exploratory factor analysis
The SPSS version 11.0 statistical package (SPSS, Chicago, IL)
for Microsoft Windows was used throughout. The data were
tabulated as the mean, standard deviation (SD) and range
for quantitative variables, and as the absolute value and
percentage in the case of qualitative variables.
A set of nine variables related to lung function (FEV1, PEF,
FEV1/FVC, RV and RV/TLC all expressed as the percentage of
predicted value), dyspnea measurements (MRC, Borg scale
and BDI) and the radiological extent of bronchiectasis
assessed by HRCT score were selected to be included in
the factor analysis. The initial step was the creation of a
Pearson’s correlation matrix of all the nine variables. The
possibility to perform factor analysis was tested by Bartlett’s
test of sphericity, and the Kaiser–Meyer–Olkin (KMO) test
was applied. Factor analysis was then used to determine the
components underlying the pattern of interrelationships
among variables without reference to a specific criterion.
The purpose of this procedure was to attribute the variables
to independent hypothetical factors. The number of factors
was based on the number of eigenvalues41 (an index of the
proportion of variance explained by successive factors,
whose magnitude was 41 of the Scree plot). The coeffi-
cients that link variables to factors are referred to as
‘‘factor loading’’, and constitute the correlation coefficients
between variables and factors. The varimax rotation
procedure was used to maximize the loadings of each
variable on one factor, whilst simultaneously minimizing the
loadings on the other factors in order to increase the
interpretability of the factors. Thus, in essence, variables
are separated into different factors with independent
information about the disease (called dimensions of the
disease). By examining which variables loaded highly on
each factor, the factors were interpreted and named. We
conducted three additional factor analyses to determine the
stability of the factor structures, and thus the robustness of
our findings. First, we repeated the analysis including only
patients with chronic colonization of sputum by Pseudomo-
nas aeruginosa (PA) or Haemophilus influenzae (HI). This was
followed by inclusion of only never-smoking patients and
finally using the absolute values of the functional para-
meters instead of the percentage of predicted values.
Results
Patient characteristics
Eighty-one patients were finally included in the study, with a
mean (SD) age of 69.5 (8.75) years; 52% were males. Fivepatients (6.2%) were current smokers (33 packs/year), and
34 patients (41.9%) were former smokers (20.2 packs/year).
The identified etiologies were: idiopathic 37 (45.6%), post-
infection 24 (29.6%); post-tuberculosis 13 (16%); allergic
bronchopulmonary aspergillosis 3 (3.7%); and rheumatoid
arthritis, immotile cilia syndrome, post-measles and poly-
myositis with a single case each. Mean values, standard
deviation and ranges for clinical ratings of dyspnea, lung
function parameters and HCRT extension score are listed in
Table 1. Agreement between the two radiologist was
excellent for the detection of bronchiectasis by HRCT scan
(kappa: 0.81).Pearson’s correlation matrix
All clinical ratings of dyspnea showed weak or no significant
correlation with spirometric function parameters (range of
correlation coefficients 0.18–0.29). However, all measure-
ments of dyspnea—especially the MRC and BDI scores—cor-
related with lung hyperinflation measures (range of
correlation coefficients 0.33–0.54). On the other hand,
the lung extension of bronchiectasis as assessed by the
HRCT score showed weak or no significant correlation with
clinical rating of dyspnea or lung function parameters
(Table 2).Factor analysis
The factor analysis of available data yielded four meaningful
independent factors, with eigenvalues of 3.63, 1.28, 1.12
and 1.07, respectively, which accounted for 84.1% of the
variance. The possibility of performing factor analysis was
confirmed by a statistically significant Bartlett’s test of
sphericity (po0.0001), and a KMO test value of 0.662.
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Table 2 Pearson’s correlation matrix of clinical rating of dyspnea, lung function parameters and disease extension score.
Parameter Dyspnea (MRC) Dyspnea (BDI) Dyspnea (Borg) HRCT score
FEV1 (% pred.) 0.26 0.27 0.17 0.19
FEV1/FVC 0.23 0.22 0.19 0.20
PEF (l/min) 0.17 0.19 0.20 0.14
RV/TLC 0.54y 0.51y 0.45y 0.17
RV 0.46y 0.41 0.33y 0.12
HRCT score 0.27 0.09 0.15 –
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; PEF: peak expiratory flow; MRC: Medical Research Council scale; BDI:
Basal Dyspnea Index; RV/TLC: ratio between residual volume and total lung capacity; HRCT: high-resolution computed tomography of
the chest.
po0.05.
ypo0.01.
Table 3 Varimax rotated factor-loading matrix for all the 81 patients.
Factor 1 (dyspnea) Factor 2 (airflow obstruction) Factor 3 (lung hyperinflation) Factor 4 (extension)
Dyspnea (BDI) 0.910 0.198 0.320 0.010
Dyspnea (MRC) 0.878 0.133 0.405 0.038
Dyspnea (Borg) 0.660 0.114 0.312 0.125
FEV1/FVC 0.115 0.918 0.230 0.023
FEV (% pred.) 0.217 0.816 0.242 0.116
PEF 0.123 0.808 0.198 0.102
RV 0.412 0.294 0.881 0.013
RV/TLC 0.483 0.116 0.717 0.021
HRCT score 0.064 0.173 0.054 0.957
Eigenvalue 3.63 1.28 1.12 1.07
% Variance 45.6 16 13.8 8.6
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; PEF: peak expiratory flow; MRC: Medical Research Council scale; BDI:
Basal Dyspnea Index; RV/TLC: ratio between residual volume and total lung capacity; HRCT: high-resolution computed tomography of
the chest. The loading factors of the variables assigned to each factor are shown in boldface.
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The first factor appeared to be ‘‘dyspnea’’. It comprised all
three clinical ratings of dyspnea (MRC, BDI and Borg scale),
which account for 45.6% of the variance. RV and RV/TLC
(particularly the latter ratio) showed significant additional
loading on the ‘‘dyspnea’’ factor.
Functional factors
Airflow obstruction parameters including FEV1, FEV1/FVC
and PEF as percentages of predicted values loaded on a
second factor which accounted for 16% of the variance.
Pulmonary hyperinflation variables (RV and RV/TLC) loaded
predominantly on a third factor and were able to explain
13.8% of the variance. Dyspnea measurements, especially
the MRC scale, loaded significantly on this factor.
Extension factor
The last factor comprised a single variable—HRCT bronch-
iectasis extension score—and was thus referred to as the‘‘lung extent’’ factor (explaining 8.6% of the total variance)
(Table 3).Subgroup factor analyses
When the analysis was repeated with absolute values of lung
function parameters instead of theoretical predicted values
(KMO test value of 0.591), the results did not significantly
change. Similarly, results were not altered by dividing the
total sample of patients on the basis of the presence or not
of chronic colonization of the sputum by any potential
pathogenic microorganisms, especially P. aeruginosa or H.
influenzae (n ¼ 49), and repeating the factor analysis in
both subgroups (KMO test values of 0.573 and 0.599,
respectively)—though these patients, and especially the
PA subgroup, presented more disease severity in terms of
disease extension of the disease (HRCT score: 5.07 vs. 3.68;
po0.01), dyspnea score (MRC: 2.31 vs. 1.55; po0.01) and
airflow obstruction (FEV1 (% predicted): 50.1 vs. 61.5,
po0.01). In the same way, factor patterns were not altered
when the subgroup of never-smoking patients (n ¼ 42) was
analyzed separately (KMO test value of 0.563). Factor
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statistically significant Bartlett’s test of sphericity
(po0.0001). Since pulmonary hyperinflation variables sig-
nificantly loaded on the ‘‘dyspnea’’ factor, an additional
factor analysis was performed with the same data in which
three factors were selected a priori (KMO test value of
0.588). The three measurements of dyspnea and pulmonary
hyperinflation variables loaded predominantly only on one
factor, resulting in a significant decrease in the total
explained variance to 70.8%; the four-factor analysis was
thus selected as a main outcome of the study.Discussion
Using factor analysis, we found that dyspnea measurements,
airflow obstruction, lung hyperinflation and pulmonary
extension of bronchiectasis were four statistically indepen-
dent and clinically interpretable dimensions or entities
characterizing patients with non-CF steady-state bronchiec-
tasis. The perception of dyspnea in patients with bronchi-
ectasis is more closely related to lung hyperinflation
assessed by RV/TLC than to lung obstruction severity as
assessed by FEV1/FVC and FEV1. To our knowledge, this is
the first study combining functional parameters, clinical
aspects and the pulmonary extent of bronchiectasis in factor
analysis to explore multivariable relationships among
outcomes in patients with non-CF bronchiectasis.
Several single parameters including airflow obstruction,
dyspnea scores, chronic PA colonization of sputum or the
extent of the disease have been used to assess the severity
of the disease or to evaluate the effect of treatment in
patients with bronchiectasis.5–7 However, evaluation of the
severity or course of the disease based on a single parameter
is usually insufficient. Thus, while the diagnosis of bronchi-
ectasis is merely morphological, its effects upon the patient
seem to comprise a series of components or dimensions with
different relative influences. Our results, using factor
analysis, showed that dyspnea scores, airway obstruction
parameters, pulmonary hyperinflation and HRCT extension
of bronchiectasis are non-overlapping dimensions suggesting
that the evaluation of patients with non-CF bronchiectasis
should include measurements of all these parameters. Some
clinical applications of this finding would be to analyze
which domains improve as a result of therapeutic interven-
tion and to analyze the patterns of improvement, or to
create a weighted severity score specific to the disease,
using the information from each of the domains studied in
the factorial analysis.
The first factor included the three different clinical
ratings of dyspnea (MRC, Borg and BDI). Interestingly,
dyspnea, in the same way as has been observed in other
obstructive airway diseases such as COPD,11,21 was much
more closely related to pulmonary hyperinflation than to
airflow obstruction assessed by FEV1/FVC and FEV1 accord-
ing to the significant additional loading of RV/TLC and RV
values on this factor. Although dyspnea in bronchiectasis is
probably a multidimensional phenomenon with some under-
lying mechanism of production such as airflow obstruction,
mucus retention or psychological factors, the relationship
between dyspnea and lung hyperinflation found in our study
seems to afford information on another important physio-pathological mechanism underlying dyspnea in these pa-
tients: inefficient respiratory muscle function under
conditions of air trapping. Of note is the observation that
the Borg scale was found to have the worst loading on the
‘‘dyspnea’’ factor and the worst correlation with functional
variables—probably reflecting the fact that the Borg scale
evaluates a different aspect of dyspnea than that evaluated
by other dyspnea ratings in patients with bronchiectasis.
The second factor included FEV1, FEV1/FVC and PEF as
expression of the different severity of airflow obstruction.
Our data were consistent with other studies on bronchiec-
tasis in relation to the notion that airway obstruction
indexes are independent of clinical variables,3,8 since these
parameters loaded on different factors in our study. On the
other hand, we have not found any relationship between
lung obstruction parameters and HRCT extension of bronch-
iectasis, in coincidence with other studies which have
usually shown correlation coefficients below 0.4.5,22 We
have eliminated age, height, and gender as explicit
variables in our factor analysis, by referring the lung
function parameters to their respective reference values.
Our third identified factor included RV and RV/TLC values,
and was called ‘‘pulmonary hyperinflation’’. Of note is the
observation that this factor is clearly separated from the
‘‘airflow obstruction’’ factor, as indicated by its loadings
indicating that in patients with non-CF bronchiectasis in the
same way as COPD,11,21 hyperinflation is an independent
characteristic of the disease state that is not always directly
linked to airway obstruction. This lack of relationship
observed in our study could be explained by the different
mechanisms of production of both phenomena. Roberts et
al.22 showed airflow obstruction in bronchiectasis assessed
by FEV1 and FEV1/FVC to be related fundamentally to
bronchial wall thickening and increased bronchial secretions
in large airways, while the presence of small airway
alterations such as bronchiolectasis, bronchiolar mucus
plugging and especially bronchiolitis—which cause func-
tional disturbances usually not detected by simple forced
spirometry—were more related to lung hyperinflation. In
this sense, Kang et al.23 found in lung resected specimens
that extended histological evidence of bronchiolitis as an
associated finding of bronchiectasis was present in 85% of
the lung lobes studied.
The last factor was the ‘‘extent’’ factor, and loaded only
one variable: the HRCT score. It would seem logical to
assume that the pulmonary extent of bronchiectasis is a key
determinant factor in defining the characteristics of
bronchiectasis disease. However, some studies appear to
suggest that the radiological extent of bronchiectasis is only
weakly correlated to the symptoms or to lung function.5,22
This was also suggested by our own results, where the extent
of bronchiectasis was seen to be a largely independent
factor accounting for only a small part of the observed
variance, and with no relationship to other clinical or
functional variables even in the bivariate correlation
analysis.
To increase the robustness of our findings, we included in
the analysis a broad range of disease severity in relation to
dyspnea, airflow obstruction (FEV1 (% predicted) from 17% to
98%) and radiological extent of bronchiectasis. Moreover, we
repeated the factor analysis under three different settings:
using the absolute values of lung function instead of the
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of patients with chronic colonization of sputum by PA or HI
as an expression of increased disease severity; and finally
including only never-smoking patients in order to reasonably
exclude COPD. We found no significant changes in the
pattern of factors in any of the subanalyses or in the
relationships between variables belonging to different
factors. Therefore, our analysis appeared to be fairly stable
even if additional parameters were taken into account or
different subgroups were studied, although it should be
mentioned that as a consequence of the reduced number of
patients in each of the sub-groups studied, these results may
be less reliable. There are some limitations in this study
which should be mentioned. On one hand, evolutive
variables, such as clinical evolution, mortality or the
number of exacerbations, were not included in our analysis
due to the transversal nature of the study. On the other
hand, important transversal variables related to bronchiec-
tasis, such as sputum volume, etiology, inflammatory status
or quality of life, were not included in the analysis because
the limited number of patients did not allow the inclusion of
more variables in the factorial analysis. The variables
selected (pulmonary function, dyspnea, and pulmonary
extension of disease) were influenced, first, by the
controversy in the literature over the association between
these variables in patients with bronchiectasis and, second,
because these are the three most commonly used variables
for evaluating severity in these types of patients.
In conclusion, our data clearly suggest that dyspnea,
airflow obstruction, pulmonary hyperinflation and pulmon-
ary extension of bronchiectasis are four independent
entities offering separate and additive information on the
pathological condition in patients with non-CF bronchiecta-
sis. Dyspnea correlates better with lung hyperinflation than
with lung obstruction—suggesting that airflow trapping
could be an important mechanism of dyspnea in patients
with bronchiectasis. We think that our study provides
important information for the designing of future studies
to assess the effect upon clinical or functional outcomes of
different therapeutic interventions in patients with non-CF
bronchiectasis.
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